BRPI1016130A2 - composto, composição farmacêutica, e , métodos para tratar ou prevenir um distúrbio e uma condição. - Google Patents
composto, composição farmacêutica, e , métodos para tratar ou prevenir um distúrbio e uma condição.Info
- Publication number
- BRPI1016130A2 BRPI1016130A2 BRPI1016130A BRPI1016130A BRPI1016130A2 BR PI1016130 A2 BRPI1016130 A2 BR PI1016130A2 BR PI1016130 A BRPI1016130 A BR PI1016130A BR PI1016130 A BRPI1016130 A BR PI1016130A BR PI1016130 A2 BRPI1016130 A2 BR PI1016130A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- treating
- preventing
- compound
- condition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16620609P | 2009-04-02 | 2009-04-02 | |
| PCT/JP2010/056404 WO2010114181A1 (en) | 2009-04-02 | 2010-04-02 | Acrylamide compounds and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016130A2 true BRPI1016130A2 (pt) | 2017-03-28 |
Family
ID=42828459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016130A BRPI1016130A2 (pt) | 2009-04-02 | 2010-04-02 | composto, composição farmacêutica, e , métodos para tratar ou prevenir um distúrbio e uma condição. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8895551B2 (pt) |
| EP (1) | EP2414332B1 (pt) |
| JP (1) | JP5643222B2 (pt) |
| CN (1) | CN102428069B (pt) |
| AU (1) | AU2010232143A1 (pt) |
| BR (1) | BRPI1016130A2 (pt) |
| CA (1) | CA2757726A1 (pt) |
| ES (1) | ES2436566T3 (pt) |
| IL (1) | IL215433A0 (pt) |
| WO (1) | WO2010114181A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5380435B2 (ja) * | 2007-05-31 | 2014-01-08 | ユーロ−セルティーク ソシエテ アノニム | アミド化合物およびその使用 |
| JP5421368B2 (ja) | 2008-08-01 | 2014-02-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用 |
| CA3187825A1 (en) * | 2020-06-25 | 2021-12-30 | Prevenial, Llc | Antimicrobial compounds and compositions |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| JPS62158291A (ja) | 1986-01-07 | 1987-07-14 | Sagami Chem Res Center | セフアロスポリン誘導体 |
| EP0330467A1 (en) * | 1988-02-23 | 1989-08-30 | Glaxo Group Limited | Heterocyclic compounds |
| ATE301457T1 (de) | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| NZ334389A (en) | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
| JP3274088B2 (ja) * | 1996-08-28 | 2002-04-15 | 三共株式会社 | 環状アミン誘導体 |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| DE10132746A1 (de) | 2001-07-05 | 2003-02-06 | Gruenenthal Gmbh | Substituierte 1-Phenethylpiperidinverbindungen |
| US7348337B2 (en) | 2002-05-28 | 2008-03-25 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US20040063744A1 (en) | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| AU2003261756A1 (en) | 2002-08-28 | 2004-03-29 | Toray Industries, Inc. | Acrylamide derivatives |
| JO2525B1 (en) | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin |
| MX2007002410A (es) | 2004-08-30 | 2007-05-07 | Neuromed Pharmaceuticals Ltd | Derivados de urea como bloqueadores de canal de calcio. |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| US20100222387A1 (en) | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
| WO2007028638A1 (en) | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
| CA2633457A1 (en) * | 2005-12-19 | 2007-06-28 | Neuromed Pharmaceuticals Ltd. | Heterocyclic amide derivatives as calcium channel blockers |
| CA2634235A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| CA2648804C (en) | 2006-04-07 | 2014-05-27 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2007125398A2 (en) | 2006-04-27 | 2007-11-08 | Pfizer Japan Inc. | : sulfonamide compounds as antagonists of the n-type calcium channel |
| EP2040698A4 (en) * | 2006-07-14 | 2011-08-10 | Shionogi & Co | OXIM CONNECTIONS AND ITS USE |
| EA200900960A1 (ru) * | 2007-01-31 | 2010-02-26 | Новартис Аг | Производные пиперидинацетамида для лечения воспалительных или аллергических заболеваний |
| WO2008124118A1 (en) | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| JP5380435B2 (ja) * | 2007-05-31 | 2014-01-08 | ユーロ−セルティーク ソシエテ アノニム | アミド化合物およびその使用 |
| EP2164325B1 (en) * | 2007-05-31 | 2013-04-24 | Shionogi&Co., Ltd. | Oxyimino compounds and the use thereof |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2009151152A1 (en) | 2008-06-11 | 2009-12-17 | Shionogi & Co., Ltd. | Oxycarbamoyl compounds and the use thereof |
| JP5421368B2 (ja) | 2008-08-01 | 2014-02-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用 |
-
2010
- 2010-04-02 CN CN201080021407.2A patent/CN102428069B/zh not_active Expired - Fee Related
- 2010-04-02 BR BRPI1016130A patent/BRPI1016130A2/pt not_active IP Right Cessation
- 2010-04-02 CA CA2757726A patent/CA2757726A1/en not_active Abandoned
- 2010-04-02 WO PCT/JP2010/056404 patent/WO2010114181A1/en not_active Ceased
- 2010-04-02 AU AU2010232143A patent/AU2010232143A1/en not_active Abandoned
- 2010-04-02 EP EP10758940.0A patent/EP2414332B1/en not_active Not-in-force
- 2010-04-02 JP JP2011542378A patent/JP5643222B2/ja active Active
- 2010-04-02 US US13/260,185 patent/US8895551B2/en active Active
- 2010-04-02 ES ES10758940.0T patent/ES2436566T3/es active Active
-
2011
- 2011-09-27 IL IL215433A patent/IL215433A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2757726A1 (en) | 2010-10-07 |
| IL215433A0 (en) | 2011-12-29 |
| CN102428069B (zh) | 2014-04-02 |
| AU2010232143A1 (en) | 2011-11-03 |
| EP2414332B1 (en) | 2013-10-23 |
| JP2012522723A (ja) | 2012-09-27 |
| US20120022069A1 (en) | 2012-01-26 |
| EP2414332A4 (en) | 2012-08-22 |
| EP2414332A1 (en) | 2012-02-08 |
| JP5643222B2 (ja) | 2014-12-17 |
| US8895551B2 (en) | 2014-11-25 |
| CN102428069A (zh) | 2012-04-25 |
| ES2436566T3 (es) | 2014-01-03 |
| WO2010114181A1 (en) | 2010-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
| BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
| BRPI0916689A2 (pt) | composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida. | |
| BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
| BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BRPI0822398A2 (pt) | Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer | |
| BRPI0916576A2 (pt) | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| BRPI0912111A2 (pt) | composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BRPI1010772A2 (pt) | composto,e, composição farmacêutica. | |
| BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
| BRPI0914918A2 (pt) | forma de dosagem farmacêutica, e, método para preparar uma forma de dosagem sólida. | |
| BRPI1008974A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3 | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |